{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:36:09Z","timestamp":1786700169879,"version":"build-2736575974"},"reference-count":50,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2714649","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:05:31Z","timestamp":1786698331000},"page":"2150-2160","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal \u2013 A modeling approach"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3446-6725","authenticated-orcid":false,"given":"Filipa de","family":"Arag\u00e3o","sequence":"first","affiliation":[{"name":"Public Health Research Centre, NOVA University of Lisbon","place":["Lisboa, Portugal"]},{"name":"Incremental Action Consulting, Lda","place":["Sobral de Monte Agra\u00e7o, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de S\u00e3o Jo\u00e3o\u200b","place":["Porto, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Claudino","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Lisboa Ocidental, EPE, Hospital S. Francisco Xavier","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Espada","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade Santa Maria\u200b, EPE","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Moita","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia do Porto","place":["Porto, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jo\u00e3o Silva","sequence":"additional","affiliation":[{"name":"Department of Biology, University of St. Andrews","place":["St. Andrews, Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f3nia","family":"Pereira","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Lda","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Santos","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Lda","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"National Strategy to Combat Cancer horizon 2030: office of the state secretariat for health promotion. 2023. [cited 2025 June 24]. https:\/\/diariodarepublica.pt\/dr\/detalhe\/despacho\/13227-2023-835712442."},{"key":"e_1_3_2_3_1","volume-title":"Registo Oncol\u00f3gico Nacional de Todos os Tumores na Popula\u00e7\u00e3o Residente em Portugal, em 2021","author":"RON","year":"2024","unstructured":"RON. Registo Oncol\u00f3gico Nacional de Todos os Tumores na Popula\u00e7\u00e3o Residente em Portugal, em 2021. Porto: Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil - EPE; 2024."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_2_5_1","unstructured":"Liga Portuguesa Contra o Cancro. Types of lymphoma; 2025 [cited 2025 June 23] https:\/\/www.ligacontracancro.pt\/linfoma-nao-hodgkin-tipos."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw175"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.498"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01306-2"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14813"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01466-6"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.213"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02572-5"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180241"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188918"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19521"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.026"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015209"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2177268"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0324-z"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720902899"},{"key":"e_1_3_2_27_1","unstructured":"Yescarta (axicabtagene ciloleucel) 0.4 \u2013 2\u2009\u00d7\u2009108 cells dispersion for infusion: summary of product characteristics; 2023."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000007000"},{"key":"e_1_3_2_29_1","unstructured":"Moura L Castro M Barreto X et al. SHARP initiative: a reflection on the future of CAR-T cell therapy in Portugal. NOVA Center for Global Health; 2025 [cited 2025 Jul 29] https:\/\/www.novaims.unl.pt\/pt\/here-now\/eventos\/iniciativa-sharp-rumo-a-inovacao\/"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.015"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001646"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxl030"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152712"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.08.010"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2260689"},{"key":"e_1_3_2_38_1","unstructured":"INFARMED Directorate of Health Technology Assessment. Public evaluation report: Yescarta (axicabtagene ciloleucel); 2025 [cited 2025 Jun 25] https:\/\/www.infarmed.pt\/documents\/15786\/3368817\/Relat%C3%B3rio+de+avalia%C3%A7%C3%A3o+de+financiamento+p%C3%BAblico+de+Yescarta+%28Axicabtagene+ciloleucel%29+%7C+LCBAG+que+recidiva+no+per%C3%ADodo+de+12+meses%C2%A0\/62387dba-1651-80e3-0c75-370a5704d3b1."},{"key":"e_1_3_2_39_1","unstructured":"INFARMED Directorate of Health Technology Assessment. Public evaluation report: Yescarta (axicabtagene ciloleucel); 2021 [cited 2025 Jun 25]. https:\/\/www.infarmed.pt\/documents\/15786\/1424140\/Relat%C3%B3rio+de+avalia%C3%A7%C3%A3o+de+financiamento+p%C3%BAblico+de+Yescarta+%28Axicabtagene+ciloleucel%29+2021\/1a73107e-e397-a6b3-7315-2444cf317249."},{"key":"e_1_3_2_40_1","unstructured":"National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy: Technology appraisal guidance TA895; 2023 [cited 2025 Jun 27]. https:\/\/www.nice.org.uk\/guidance\/ta895."},{"key":"e_1_3_2_41_1","unstructured":"National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies: Technology appraisal guidance TA872; 2023 [cited 2025 Jun 27]. https:\/\/www.nice.org.uk\/guidance\/ta872."},{"key":"e_1_3_2_42_1","volume-title":"Axicabtagene ciloleucel (Yescarta): CADTH reimbursement recommendation: Indication: for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy","author":"Canadian Agency for Drugs and Technologies in Health","year":"2023","unstructured":"Canadian Agency for Drugs and Technologies in Health. Axicabtagene ciloleucel (Yescarta): CADTH reimbursement recommendation: Indication: for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023."},{"key":"e_1_3_2_43_1","unstructured":"Health Canada. Summary basis of decision for Yescarta; 2019 [cited 2025 Jul 29]. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SBD00442."},{"key":"e_1_3_2_44_1","unstructured":"Instituto Nacional de Estat\u00edstica. Probability of dying - qx (2007 methodology) by place of residence (NUTS - 2024) sex and age; annual; 2024 [cited 2025 Oct 31]. https:\/\/www.ine.pt\/bddXplorer\/htdocs\/minfo.jsp?var_cd=0013460&lingua=EN."},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02226-5"},{"key":"e_1_3_2_46_1","unstructured":"Gore C Lazarus J Baptista Leite R. Road to elimination: barriers and best practices in Hepatitis C management. Overview of the status of HCV care in Europe and Australia; 2017 [cited 2025 Jun 25]. https:\/\/media-publications.bcg.com\/BCG-Road-to-Elimination.pdf."},{"key":"e_1_3_2_47_1","unstructured":"INFARMED. Financing of medications for spinal muscular atrophy; 2021 [cited 2025 Jul 30]. https:\/\/www.infarmed.pt\/documents\/15786\/4183428\/Comunicado+de+Imprensa+-+Aprovado+Financiamento+P%C3%BAblico+de+medicamento+para+Atrofia+Muscular+Espinal%C2%A0\/625f13db-3cf1-556d-c5e5-88b3b95a5ab8."},{"key":"e_1_3_2_48_1","unstructured":"European Observatory on Health Systems and Policies. Portugal health system summary 2024; 2025 [cited 2025 Jun 25]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/381446\/9789289014564-eng.pdf?sequence=1&isAllowed=y."},{"key":"e_1_3_2_49_1","unstructured":"Gilead Sciences Lda. Data on file; 2025."},{"key":"e_1_3_2_50_1","unstructured":"INFARMED I.P. Health technology assessment report; 2025 [cited 2025 Nov 26]. https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.017"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2714649","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2714649","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2714649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:05:36Z","timestamp":1786698336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2714649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2714649"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2714649","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}